AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Nexium Dyspepsia/AST
Phase 3
Completed
- Conditions
- Gastrointestinal DiseaseSigns and Symptoms, DigestiveDyspepsia
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1200
- Registration Number
- NCT00251992
- Locations
- 🇬🇧
Research Site, Watford, United Kingdom
Chest Pain Pilot Study
Phase 3
Completed
- Conditions
- Chest PainGastroesophageal Reflux
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT00251901
- Locations
- 🇸🇪
Research Site, Östersund, Sweden
A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer
Phase 3
Completed
- Conditions
- Gastrointestinal Hemorrhage
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2011-06-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1312
- Registration Number
- NCT00251979
- Locations
- 🇬🇧
Research Site, Leeds, United Kingdom
GALLANT 8 Tesaglitazar Add-on to Metformin
Phase 3
Terminated
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2009-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 555
- Registration Number
- NCT00251953
- Locations
- 🇬🇧
Research Site, Wrexham, United Kingdom
ASTERIX: Low Dose ASA and Nexium
Phase 3
Completed
- Conditions
- Gastroesophageal Reflux
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 960
- Registration Number
- NCT00251966
- Locations
- 🇬🇧
Research Site, Edinburgh, United Kingdom
Nexium Dyspepsia/AST
Phase 3
Completed
- Conditions
- Gastrointestinal DiseaseSigns and Symptoms, DigestiveDyspepsia
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1500
- Registration Number
- NCT00251914
- Locations
- 🇨🇭
Research Site, St. Gallen, Switzerland
GALLANT 7 Tesaglitazar Add-on to Sulphonylurea
Phase 3
Terminated
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2008-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 555
- Registration Number
- NCT00251940
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2005-11-02
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 77
- Registration Number
- NCT00247481
- Locations
- 🇫🇷
Research Site, Villejuif Cedex, France
Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT
Phase 2
Completed
- Conditions
- Bladder Cancer
- Interventions
- First Posted Date
- 2005-11-01
- Last Posted Date
- 2008-10-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 125
- Registration Number
- NCT00246974
- Locations
- 🇩🇪
Research Site, Ulm, Germany
Arimidex Observational: Reason for and Effect of Change From Tamoxifen
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2005-11-01
- Last Posted Date
- 2007-10-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT00246961
- Locations
- 🇳🇱
Research Site, Zutphen, Netherlands
🇳🇱Research SIte, Dordrecht, Netherlands
© Copyright 2025. All Rights Reserved by MedPath